OBJECTIVE: To analyze the relationship between clinical benefits and immunological changes in patients with systemic sclerosis (SSc) treated with autologous hematopoietic stem cell transplantation (HSCT). METHODS: Ten patients with SSc were treated with high-dose cyclophosphamide followed by highly purified CD34+ cells (n=5) or unpurified grafts (n=5). Two groups of patients were retrospectively constituted based on their clinical response (good responders, n=7; and poor responders, n=3). As well as clinical findings, immunological reconstitution through autologous HSCT was assessed by fluorescence-activated cell sorter analysis, quantification of signal joint T cell receptor rearrangement excision circles (sjTREC), reflecting the thymic function, and foxp3, a key gene of regulatory T cells, mRNA levels. RESULTS: Patients' clinical and immunological findings were similar between good and poor responders, or CD34-purified and unpurified groups at inclusion. The sjTREC values were significantly suppressed at 3 months after autologous HSCT in good responders compared with poor responders (p=0.0152). Reconstitution of CD4+CD45RO- naive T cells was delayed in good responders compared with poor responders. The phenotype of other lymphocytes, cytokine production in T cells, and foxp3 gene expression levels after autologous HSCT did not correlate with clinical response in good or poor responders. Clinical and immunological findings after autologous HSCT were similar between CD34-purified and unpurified groups. CONCLUSION: Our results suggest that immunosuppression intensity, sufficient to induce transient suppression of thymic function, is attributable to the feasible clinical response in patients with SSc treated with autologous HSCT. Appropriate monitoring of sjTREC values may predict clinical benefits in transplanted SSc patients after autologous HSCT.
OBJECTIVE: To analyze the relationship between clinical benefits and immunological changes in patients with systemic sclerosis (SSc) treated with autologous hematopoietic stem cell transplantation (HSCT). METHODS: Ten patients with SSc were treated with high-dose cyclophosphamide followed by highly purified CD34+ cells (n=5) or unpurified grafts (n=5). Two groups of patients were retrospectively constituted based on their clinical response (good responders, n=7; and poor responders, n=3). As well as clinical findings, immunological reconstitution through autologous HSCT was assessed by fluorescence-activated cell sorter analysis, quantification of signal joint T cell receptor rearrangement excision circles (sjTREC), reflecting the thymic function, and foxp3, a key gene of regulatory T cells, mRNA levels. RESULTS:Patients' clinical and immunological findings were similar between good and poor responders, or CD34-purified and unpurified groups at inclusion. The sjTREC values were significantly suppressed at 3 months after autologous HSCT in good responders compared with poor responders (p=0.0152). Reconstitution of CD4+CD45RO- naive T cells was delayed in good responders compared with poor responders. The phenotype of other lymphocytes, cytokine production in T cells, and foxp3 gene expression levels after autologous HSCT did not correlate with clinical response in good or poor responders. Clinical and immunological findings after autologous HSCT were similar between CD34-purified and unpurified groups. CONCLUSION: Our results suggest that immunosuppression intensity, sufficient to induce transient suppression of thymic function, is attributable to the feasible clinical response in patients with SSc treated with autologous HSCT. Appropriate monitoring of sjTREC values may predict clinical benefits in transplanted SSc patients after autologous HSCT.
Authors: J Baraut; E I Grigore; F Jean-Louis; S H Khelifa; C Durand; F Verrecchia; D Farge; L Michel Journal: Bone Marrow Transplant Date: 2013-12-23 Impact factor: 5.483
Authors: Lucas C M Arruda; Kelen C R Malmegrim; João R Lima-Júnior; Emmanuel Clave; Juliana B E Dias; Daniela A Moraes; Corinne Douay; Isabelle Fournier; Hélène Moins-Teisserenc; Antônio José Alberdi; Dimas T Covas; Belinda P Simões; Pauline Lansiaux; Antoine Toubert; Maria Carolina Oliveira Journal: Blood Adv Date: 2018-01-23
Authors: Maynara Santana-Gonçalves; Djúlio Zanin-Silva; Álvaro Henrique-Neto; Daniela A Moraes; Marianna Y Kawashima-Vasconcelos; João R Lima-Júnior; Juliana B E Dias; Vinícius Bragagnollo; Júlia T C de Azevedo; Dimas T Covas; Kelen C R Malmegrim; Leandra Ramalho; Maria Carolina Oliveira Journal: Ther Adv Musculoskelet Dis Date: 2022-03-28 Impact factor: 5.346
Authors: Marianna Y Kawashima-Vasconcelos; Maynara Santana-Gonçalves; Djúlio C Zanin-Silva; Kelen C R Malmegrim; Maria Carolina Oliveira Journal: Front Immunol Date: 2022-08-11 Impact factor: 8.786